The National Institute of Dental and Craniofacial Research has provided a $3.24 million grant to investigate an injectable biomaterial designed to deliver immunotherapy directly to oral cancer tumors.
The biomaterial, SABERGel, combines four therapeutic functions within the tumor environment, aiming to prevent cancer recurrence and overcome the tumor’s ability to suppress the body’s immune response, according to a Nov. 16 news release from UTHealth Houston.
The peptide-based hydrogel is designed to allow different agents to be released at different rates, coordinating the recruitment and activation of cancer-fighting immune cells while blocking biological pathways that suppress their activity.
Source: NIH awards $3.2M multi-institutional grant to study new oral cancer treatment / Becker’s Dental

